Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bosutinib + ropeginterferon alfa-2b
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
The combination of bosutinib and ropeginterferon alfa-2b is an investigational therapeutic regimen being evaluated for the frontline treatment of newly diagnosed chronic myeloid leukemia (CML). This combination therapy, currently under investigation in the Phase 2 BOSURE trial sponsored by St. Olavs Hospital, pairs bosutinib, a second-generation tyrosine kinase inhibitor (TKI), with ropeginterferon alfa-2b, a long-acting monopegylated interferon. Bosutinib functions by inhibiting the BCR-ABL1 fusion protein and SRC family kinases, which are critical for the proliferation of leukemic cells. Ropeginterferon alfa-2b acts as an immunomodulator, binding to Type I interferon receptors to stimulate an immune response against leukemic stem cells. The primary objective of this combination is to enhance deep molecular response (DMR) rates and increase the number of patients who can successfully achieve treatment-free remission (TFR).
- Other names
- Ropeginterferon alfa-2bBosutinib
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on bosutinib + ropeginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bosutinib + ropeginterferon alfa-2b.